Company intelligence / Profile preview
Gedeon Richter Plc
Budapest, Hungarygedeonrichter.com ↗
- Ownership
- Private
- Employees
- ~11603
- Development stage
- Commercial
01
Overview
Gedeon Richter has multiple commercial products and a robust pipeline. Recent developments include positive CHMP opinion for biosimilar denosumab products (Junod® and Yaxwer®) for bone disease and osteoporosis, and submission to EMA for biosimilar tocilizumab for multiple indications[1][3].
- Therapeutic areas
- GastroenterologyCardiovascularRheumatologyImmunologyEndocrinologyWomen's HealthNeurologyInfectious Diseases
- Modalities
- Small moleculesBiologicsBiosimilarsGeneric drugs
- Industry
- Biotech
02
Drug pipeline
24 assets23 more assets in the full pipeline.
Request access →03
Partnerships
AbbVieBio-Thera SolutionsFormycon (9.08% equity)Themis MedicareHelm AG[2][6]
Beyond the preview
Go deeper on Gedeon Richter Plc.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gedeon Richter Plc.